Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




AI-Powered Prostate Cancer Diagnosis Tool Accurately Identifies and Classifies Tumors

By LabMedica International staff writers
Posted on 14 Mar 2023

Prostate adenocarcinoma is the most prevalent form of prostate cancer, representing around 90% of all prostate cases, and is also the second most commonly occurring cancer in men, demonstrating a steady increase in prevalence worldwide. Now, a powerful tool to detect prostatic adenocarcinoma leverages advanced machine learning algorithms to accurately identify and classify malignant and benign areas in prostate biopsies, thereby improving diagnostic accuracy and patient outcomes.

Qritive (Singapore) has launched a new AI (Artificial Intelligence) module, QAi Prostate, for prostate cancer diagnosis that uses advanced machine learning algorithms to analyze whole slide images of prostate core needle biopsies, identify prostatic adenocarcinoma region, and segment and classify them into benign and malignant areas. QAi Prostate uses whole slide images as well as regions of interest (ROI) for screening adenocarcinoma. QAi Prostate provides a detailed summary of the tumor size and percentage for each slide or ROI, allowing pathologists to quickly make more informed and accurate diagnoses, thus reducing the time to treatment for patients.

QAi Prostate has been built using a comprehensive dataset that has passed through extensive testing and validation procedures to ensure it meets the required clinical metrics and reliability standards. It is compatible with all standard digital pathology systems and can be easily integrated into existing workflows using Open API interface through a customizable middleware. It allows for secured communication using standard SSL encryption and the middleware as a single point of entry with role-based access to ensure advanced security and compliance. QAi Prostate is currently not approved by the FDA or CE marked and can be deployed for research use or as laboratory developed test only.

"We are excited to introduce this new AI module for prostate cancer diagnosis," said Dr. Kaveh Taghipour, CTO of Qritive. "QAi Prostate has been developed using millions of data points and thousands of hours of expert knowledge. This technology has the potential to improve the accuracy and speed of prostate cancer diagnosis significantly, leading to better outcomes for patients."

Related Links:
Qritive 

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Coagulation Analyzer
CS-2400
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.